Angiogenesis is a critical process in cancer progression, as it enables tumor growth and metastasis by supplying oxygen, nutrients, and removing waste. Angiogenesis and lymphangiogenesis are regulated by activators and inhibitors, with angiogenic factors such as VEGF, bFGF, and others playing key roles. VEGF is a potent angiogenic factor that promotes blood vessel formation, while VEGF-C and VEGF-D are involved in lymphangiogenesis. Angiogenic inhibitors like angiostatin and endostatin can suppress tumor growth by inhibiting vascular formation. However, antiangiogenic therapies have not shown significant long-term survival benefits in cancer patients. Despite this, combining antiangiogenic agents with conventional treatments may improve outcomes. Angiogenesis is closely linked to cancer prognosis, with higher VEGF expression correlating with worse outcomes. Tumor vasculature is often abnormal, leading to poor drug delivery and resistance to therapy. Normalizing tumor vasculature is an emerging strategy in antiangiogenic treatment. Current research focuses on developing new therapies that target both angiogenesis and tumor growth, aiming to improve cancer treatment outcomes.Angiogenesis is a critical process in cancer progression, as it enables tumor growth and metastasis by supplying oxygen, nutrients, and removing waste. Angiogenesis and lymphangiogenesis are regulated by activators and inhibitors, with angiogenic factors such as VEGF, bFGF, and others playing key roles. VEGF is a potent angiogenic factor that promotes blood vessel formation, while VEGF-C and VEGF-D are involved in lymphangiogenesis. Angiogenic inhibitors like angiostatin and endostatin can suppress tumor growth by inhibiting vascular formation. However, antiangiogenic therapies have not shown significant long-term survival benefits in cancer patients. Despite this, combining antiangiogenic agents with conventional treatments may improve outcomes. Angiogenesis is closely linked to cancer prognosis, with higher VEGF expression correlating with worse outcomes. Tumor vasculature is often abnormal, leading to poor drug delivery and resistance to therapy. Normalizing tumor vasculature is an emerging strategy in antiangiogenic treatment. Current research focuses on developing new therapies that target both angiogenesis and tumor growth, aiming to improve cancer treatment outcomes.